USPTO serial 88278778
EPCARG
Reviewed by CopyMark Law Group
Reg. 6026619Status 710
- Filing date
- Status date
- Registration date
- Apr 7, 2020
- Examiner
- MIZELLE HOWARD, DEZMONA JULYE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with EPCARG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
LEIGH ANN LINDQUIST
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC2000 PENNSYLVANIA AVENUE NW, SUITE 9000WASHINGTON, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological, biochemical and biotechnological products and preparations for industrial and scientific purposes, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms, protein-based capsids or particles as well as fragments, fractions and derivatives thereof | SECTION 8 - CANCELLED | — |
| 005 | Diagnostic preparations for medical purposes; vaccines; pharmaceutical preparations, namely, adjuvants, carriers for active ingredients and drug delivery systems based on an engineered protein capsule for medical use in humans or animals, implants comprising active ingredients for the prevention or treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation; all the aforementioned goods only being either drug delivery agents based on an engineered protein capsule or pharmaceutical products or preparations for use with a drug delivery agent or system based on an engineered protein capsule; none of the aforementioned goods for use in connection with the treatment or prevention of hepatitis | SECTION 8 - CANCELLED | — |
| 040 | Manufacture of pharmaceutical products, medicinal products, medicaments from pharmaceutical compositions for third parties; all the aforementioned only in relation to drug delivery agents or systems based on an engineered protein capsule and/or pharmaceutical products or preparations for use with a drug delivery agent or system based on an engineered protein capsule; none of the aforementioned for use in connection with the treatment or prevention of hepatitis | SECTION 8 - CANCELLED | — |
| 042 | Scientific research and development for third parties, in particular in the fields of medicine, pharmacy, diagnostics, chemistry, biology, biochemistry and biotechnology; scientific research and development with regard to the manufacture of pharmaceutical preparations, carriers for active ingredients and drug delivery systems for use in humans or animals, for third parties; development of pharmaceutical preparations, namely, medical products for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation, for third parties | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named EPCARG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Apr 7, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 26, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 26, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 26, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 26, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 26, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 7, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 17, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 17, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 16, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 16, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 16, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 22, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 1, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 1, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 1, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 1, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 15, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 15, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 15, 2019 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 9, 2019 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 9, 2019 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jul 17, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 17, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 17, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 27, 2019 | DMCC | DATA MODIFICATION COMPLETED | — |
| Jun 27, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 12, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 10, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 10, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 10, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 21, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 21, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 17, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 10, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 9, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 9, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 12, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 25, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Feb 21, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 20, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 14, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 31, 2019 | NWAP | NEW APPLICATION ENTERED | — |